About the Foundation

What is GBA and how does it relate to Parkinson’s Disease?

The GBA gene (Glucosylceramidase Beta Acid) encodes the protein glucocerebrosidase, or GCase. GCase functions to allow a brain cell to clear debris via a cellular component known as the lysosome. Those who have mutations in the GBA gene are at higher risk for Parkinson’s Disease (PD) because they have a reduction in GCase activity and can’t effectively remove the debris. It is hypothesized that this excess debris aggregates, causing clumps of alpha synuclein, which is toxic to brain cells.

The percentage of patients that have Parkinson’s with GBA is believed to be roughly 5 – 7% of the overall Parkinson’s population, however therapeutic breakthroughs identified through our work have the potential to benefit all PD patients as well as others suffering from neurodegenerative diseases.

About our Founder

“The mission and goals of the Foundation are very specific. It will be focused solely on rapidly converting scientific ideas and experimental drugs into FDA approved therapeutics to treat and prevent the onset of Parkinson’s disease in GBA-mutation carriers.” 

– Jonathan Silverstein 

Jonathan T. Silverstein, J.D./M.B.A., is a General Partner and a Co-Head of Global Private Equity at OrbiMed, one of the world’s largest fully dedicated healthcare fund managers with five offices around the globe. Mr. Silverstein joined OrbiMed in 1998 and has been on the board of several dozen biotech companies over the last two decades. During his tenure, OrbiMed has invested in healthcare companies that have led to over 60 FDA approved therapeutics, medical devices and diagnostics.

With a particular interest in rare diseases, Mr. Silverstein has been the chairman of several biotechnology companies focused on these “orphan” drugs, including: Enobia (sold to Alexion), Intercept (ICPT), Audentes (BOLD) and a director of Ascendis (ASND) and Rhythm Therapeutics (RYTM). For the last seven years (2012 to 2018), Forbes® Magazine named Mr. Silverstein one of the top 100 venture capitalists in the world when it placed him on the “Forbes Midas List”.

After being diagnosed with Parkinson’s Disease, Jonathan learned that he was a carrier of the GBA mutation which had triggered his disease.  He immediately established The Silverstein Foundation, and gathered a team of the worlds leading GBA-PD experts to help him find a cure.  Over his 20 years of experience in healthcare venture capital, Jonathan has had success in investing in therapeutics to treat PD and other rare diseases, making him uniquely positioned to take on this challenge.

Mr. Silverstein has a J.D. and an M.B.A. from the University of San Diego, and a B.A. in Economics from Denison University.